259 related articles for article (PubMed ID: 23117645)
1. [Introduction].
Valle Bernad R
Rev Clin Esp; 2012 Jan; 212 Suppl 1():1-2. PubMed ID: 23117645
[No Abstract] [Full Text] [Related]
2. Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Ezekowitz MD; Kent AP
Circulation; 2014 Oct; 130(17):1505-14. PubMed ID: 25332278
[No Abstract] [Full Text] [Related]
3. New oral anticoagulants in the management of venous thromboembolism: a major advance?
Sciascia S; Hunt BJ
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):487-8. PubMed ID: 25150440
[No Abstract] [Full Text] [Related]
4. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
5. Switching between oral anticoagulants.
Strasser KM; Qasem A; Madhusudhana S
Hosp Pract (1995); 2014 Aug; 42(3):68-74. PubMed ID: 25255408
[TBL] [Abstract][Full Text] [Related]
6. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Oberhofer E
MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289
[No Abstract] [Full Text] [Related]
7. Target-specific oral anticoagulants: practice issues for the clinician.
Plitt A; Giugliano RP
Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406
[TBL] [Abstract][Full Text] [Related]
8. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Arepally GM; Ortel TL
Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
[TBL] [Abstract][Full Text] [Related]
9. [Improvements in oral anticoagulant therapy for atrial fibrillation].
Briongos Figuero S; García Santos-Gallego C; Badimón JJ
Med Clin (Barc); 2013 Dec; 141(11):487-93. PubMed ID: 23597953
[TBL] [Abstract][Full Text] [Related]
10. Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Turagam MK; Velagapudi P; Bongu NR; Kocheril AG
Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):79-86. PubMed ID: 25088126
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Bauer KA
Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725
[No Abstract] [Full Text] [Related]
12. Overview of the new oral anticoagulants: opportunities and challenges.
Yeh CH; Hogg K; Weitz JI
Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
[TBL] [Abstract][Full Text] [Related]
13. Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Truffa AA; Lopes RD; Newby LK
Postgrad Med; 2013 Mar; 125(2):146-57. PubMed ID: 23816780
[TBL] [Abstract][Full Text] [Related]
14. [Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Di Pasquale G; Riva L
G Ital Cardiol (Rome); 2011 Sep; 12(9):556-65. PubMed ID: 21892216
[TBL] [Abstract][Full Text] [Related]
15. A new era for anticoagulation in atrial fibrillation.
Mega JL
N Engl J Med; 2011 Sep; 365(11):1052-4. PubMed ID: 21870977
[No Abstract] [Full Text] [Related]
16. Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
Spanos K; Giannoukas AD
Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353. PubMed ID: 25556084
[No Abstract] [Full Text] [Related]
17. Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):127. PubMed ID: 25882231
[No Abstract] [Full Text] [Related]
18. Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353-4. PubMed ID: 25556083
[No Abstract] [Full Text] [Related]
19. Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons.
Hurst KV; Lee R; Milosevic I; Handa A
Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):126-7. PubMed ID: 25933476
[No Abstract] [Full Text] [Related]
20. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
